Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
暂无分享,去创建一个
Ravi Salgia | Edward A Fox | Erik Schaefer | W. Richards | D. Sugarbaker | J. Christensen | R. Salgia | M. Tretiakova | M. Hansen | E. Fox | P. Ma | E. Schaefer | A. Husain | K. Naoki | Patrick C Ma | Katsuhiko Naoki | James G Christensen | R. Jagadeeswaran | Aliya N Husain | David Sugarbaker | S. Jagadeesh | V. Nallasura | A. Lader | Maria S Tretiakova | Mark Hansen | Ramasamy Jagadeeswaran | Simha Jagadeesh | Vidya Nallasura | Alan Lader | William Richards
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] S. J. Kim,et al. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] P Zola,et al. Overexpression of the MET/HGF receptor in ovarian cancer , 1994, International journal of cancer.
[4] R. Salgia,et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.
[5] T. Blundell,et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] Christian Wiesmann,et al. Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor , 2004, The EMBO journal.
[7] N. Heisterkamp,et al. CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells (*) , 1995, The Journal of Biological Chemistry.
[8] R. Salgia,et al. Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in Small cell lung cancer , 2004 .
[9] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Watkins,et al. The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer , 2004, Clinical Cancer Research.
[11] T. Nakamura,et al. Organization of the human hepatocyte growth factor-encoding gene. , 1991, Gene.
[12] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[13] P. Comoglio,et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases , 2000, International journal of cancer.
[14] J. Christensen,et al. c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.
[15] K. Inoue,et al. Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma. , 1998, Acta medica Okayama.
[16] P. Comoglio,et al. Overexpression of the met/HGF receptor in renal cell carcinomas , 1996, International journal of cancer.
[17] J. Baselga. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Salgia,et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] S. Giordano,et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas , 2001, Journal of cellular physiology.
[20] P. Comoglio,et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. , 2002, Cancer research.
[21] J. Stamos,et al. The Sema domain of Met is necessary for receptor dimerization and activation. , 2004, Cancer cell.
[22] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[23] G. Sledge,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] David H. Johnson. Gefitinib (Iressa) trials in non-small cell lung cancer. , 2003, Lung cancer.
[25] S. Lipkowitz,et al. A Conserved DpYR Motif in the Juxtamembrane Domain of the Met Receptor Family Forms an Atypical c-Cbl/Cbl-b Tyrosine Kinase Binding Domain Binding Site Required for Suppression of Oncogenic Activation* , 2004, Journal of Biological Chemistry.
[26] R. Herbst,et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[28] David I. Smith,et al. A role for common fragile site induction in amplification of human oncogenes. , 2002, Cancer cell.
[29] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[30] P. Comoglio,et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. , 1996, British Journal of Cancer.
[31] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[32] J. Christensen,et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.
[33] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Paoli,et al. Protein folds propelled by diversity. , 2001, Progress in biophysics and molecular biology.
[35] Isaac S Kohane,et al. Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines , 2004, Cancer biology & therapy.
[36] J. Luketich,et al. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. , 1998, The Annals of thoracic surgery.
[37] W. Linehan,et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.
[38] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] H. Band,et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. , 2001, Molecular cell.
[40] S. Law,et al. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] D. Dykxhoorn,et al. Killing the messenger: short RNAs that silence gene expression , 2003, Nature Reviews Molecular Cell Biology.
[42] R. Salgia,et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.
[43] David H. Johnson. Targeted therapy in non-small cell lung cancer: myth or reality. , 2003, Lung cancer.
[44] M. Meyerson,et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.